Zobrazeno 1 - 10
of 17
pro vyhledávání: '"L C, Drinkard"'
Autor:
Jemi Olak, Brian L. Samuels, Daniel J. Haraf, Mark K. Ferguson, Philip C. Hoffman, Harvey M. Golomb, L. C. Drinkard, Everett E. Vokes, Gregory A. Masters, Stuart A. Krauss
Publikováno v:
Journal of Clinical Oncology. 16:2157-2163
PURPOSE The cisplatin-vinorelbine regimen has superior activity in advanced non-small-cell lung cancer (NSCLC). We conducted a phase I trial to identify the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of this regimen with concomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::868b8dfc409781708f953beef7b85e8b
https://doi.org/10.1200/jco.1998.16.6.2157
https://doi.org/10.1200/jco.1998.16.6.2157
Autor:
Rosemarie Mick, Brian L. Samuels, Harvey M. Golomb, L. C. Drinkard, Alfred Guaspari, Gregory A. Masters, Ai-ly Hsieh, Philip C. Hoffman, Everett E. Vokes
Publikováno v:
Journal of Clinical Oncology. 15:884-892
PURPOSE We designed a phase I dose-escalation study of vinorelbine on a novel (daily-times-three) schedule with ifosfamide with granulocyte colony-stimulating factor (G-CSF) support to define the dose-limiting toxicity (DLT) and maximum-tolerated dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9372e8ee203ce8fabbd268a05cfa1f45
https://doi.org/10.1200/jco.1997.15.3.884
https://doi.org/10.1200/jco.1997.15.3.884
Autor:
Mark K. Ferguson, Philip C. Hoffman, Everett E. Vokes, N. J. Lane, L. C. Drinkard, S. Watson, N. J. Vogelzang, Daniel J. Haraf, Harvey M. Golomb
Publikováno v:
Cancer Chemotherapy and Pharmacology. 35:304-312
Concomitant chemoradiotherapy with cisplatin and combination chemotherapy in the neoadjuvant setting have both shown promising results.Purpose: To identify a locally and systemically active concomitant chemoradiotherapy regimen incorporating high-dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf9a1fc2312c5b77a36cb70afb29be9
https://doi.org/10.1007/bf00689449
https://doi.org/10.1007/bf00689449
Autor:
Daniel J. Haraf, Everett E. Vokes, Laurie B. Reeder, L. C. Drinkard, Mark K. Ferguson, Philip C. Hoffman
Publikováno v:
Annals of Surgical Oncology. 2:101-106
Background: We designed a trial of intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction to assess tumor response and operability after neoadjuvant chemotherapy and to determine the impact of trimodality therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cde9758f2c4bdcd3b0ec5484ece729a9
https://doi.org/10.1007/bf02303623
https://doi.org/10.1007/bf02303623
Autor:
John Albertini, Maria Medenica, Joseph M. Baron, Kenneth Beer, Allan L. Lorincz, Timothy J. Swartz, L. C. Drinkard
Publikováno v:
International Journal of Dermatology. 33:860-862
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74288ae7b6c5c79c79fcbbf5c9aaf650
https://doi.org/10.1111/j.1365-4362.1994.tb01022.x
https://doi.org/10.1111/j.1365-4362.1994.tb01022.x
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 9(6)
Summary Purpose: To define the activity and toxicity of preoperative chemotherapy and postoperative concomitant chemoradiotherapy in patients with carcinoma of the esophagus, and to determine the effect on survival in patients treated with this appro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fffead3b4853bb4a45c21e0d20e28c9e
https://pubmed.ncbi.nlm.nih.gov/9681079
https://pubmed.ncbi.nlm.nih.gov/9681079
Publikováno v:
Seminars in oncology. 25(1 Suppl 2)
Ifosfamide and vinorelbine have demonstrated single-agent activity against advanced non-small cell lung cancer. The dose-limiting toxicity of each agent is myelosuppression. Several trials have studied this combination to determine its toxicity and e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::03efdb108347d83ae3b73c2e392321ed
https://pubmed.ncbi.nlm.nih.gov/9535205
https://pubmed.ncbi.nlm.nih.gov/9535205
Publikováno v:
Seminars in oncology. 23(3 Suppl 7)
Current clinical investigations in the palliative care setting for patients with non-small cell lung cancer are focused on new drugs and combinations. The goal of these studies is to identify more effective and/or less toxic therapy. At the Universit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9e12ff971637d7b5a6132e2d1b3b02b3
https://pubmed.ncbi.nlm.nih.gov/8711496
https://pubmed.ncbi.nlm.nih.gov/8711496
Autor:
P C, Hoffman, G A, Masters, L C, Drinkard, S A, Krauss, B L, Samuels, H M, Golomb, E E, Vokes
Publikováno v:
Seminars in oncology. 23(3 Suppl 6)
Two studies were performed to determine the maximum tolerated dose (MTD) of paclitaxel and vinorelbine, respectively, in combination with a fixed dose of ifosfamide in previously untreated patients with stage IIIB or IV non-small cell lung cancer. Re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3df8e6d3cdd7c7f39a904ef89e96b42e
https://pubmed.ncbi.nlm.nih.gov/8677441
https://pubmed.ncbi.nlm.nih.gov/8677441
Autor:
E E, Vokes, D J, Haraf, G A, Masters, P C, Hoffman, L C, Drinkard, M, Ferguson, J, Olak, S, Watson, H M, Golomb
Publikováno v:
Seminars in oncology. 23(2 Suppl 5)
Most patients with advanced solid tumors of the chest will have local and/or distant disease progression despite standard therapy. Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aa5f92beede27686f6df1b029ee4c86e
https://pubmed.ncbi.nlm.nih.gov/8610237
https://pubmed.ncbi.nlm.nih.gov/8610237